Condition
Relapsed Large B-cell Lymphoma
Total Trials
3
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT07473167Phase 1RecruitingPrimary
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
NCT06811272Phase 2RecruitingPrimary
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
NCT04836507Phase 1RecruitingPrimary
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
Showing all 3 trials